Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer

• Published in: Lung cancer (Amsterdam, Netherlands) Vol. 90; no. 1; pp. 85 - 91
• Main Authors: Sjøblom, Bjørg, Grønberg, Bjørn H, Benth, Jūratė Šaltytė, Baracos, Vickie E, Fløtten, Øystein, Hjermstad, Marianne J, Aass, Nina, Jordhøy, Marit
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 01-10-2015
• Subjects: Administration, Intravenous; Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Body composition; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - pathology; Chemotherapy toxicity; Cross-Sectional Studies; Deoxycytidine - administration & dosage; Deoxycytidine - adverse effects; Deoxycytidine - analogs & derivatives; Drug therapy; Female; Haematological toxicity; Hematologic Diseases - chemically induced; Hematology, Oncology and Palliative Medicine; Humans; Induction Chemotherapy; Lean body mass; Lung Neoplasms - drug therapy; Lung Neoplasms - pathology; Male; Muscle, Skeletal - anatomy & histology; Muscle, Skeletal - drug effects; Muscle, Skeletal - pathology; Neoplasm Staging; Non-small cell lung cancer; Pulmonary/Respiratory; Skeletal muscle; Vinblastine - administration & dosage; Vinblastine - adverse effects; Vinblastine - analogs & derivatives; Wasting syndrome; Chemotherapy toxicity; Non-small cell lung cancer; Lean body mass; Haematological toxicity; Drug therapy; Wasting syndrome; Body composition; Skeletal muscle
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2015.07.001

Highlights • Body surface area (BSA) does not reflect differences in body compostion. • Dose estimation by BSA gave large variations in dose per kg lean body mass (LBM). • Higher dose/ kg LBM was a significant predictor of severe haematological toxicity. • Taking LBM into account in dose estimation might help reduce chemotherapy toxicity.